Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed) National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)". This grant aims to support basic and applied research to understand the mechanisms for establishing, developing, and maintaining immunity to HIV in early life, specifically from birth to less than 12 years of age. The research will focus on the impact of prophylactic vaccination and broadly neutralizing HIV antibodies (bNAbs) in protecting against the acquisition of HIV infection. The funding instrument type for this opportunity is a Cooperative Agreement, and there is no cost sharing or matching requirement. The grant falls under the category of Health and is classified as discretionary. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The closing date for applications is October 9, 2024. The maximum award ceiling for this grant is $750,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-029.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-029.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)". This grant aims to support the translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, including Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing for clinical testing.
The grant will provide funding for various activities such as technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.
The grant opportunity falls under the category of Health and is classified as a Cooperative Agreement. The funding does not require cost sharing or matching. The maximum award ceiling for this grant is $3,000,000. The eligibility for this grant is open to various entities, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession.
The closing date for this grant opportunity is March 14, 2025, and the archive date is April 19, 2025. For more information and to apply, please visit the following link: [Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-033.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed) National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed)". This grant aims to support research in three main areas: 1) defining associations between variations in HLA and KIR genetic regions and immune-mediated diseases, 2) elucidating mechanisms underlying these associations to advance therapeutic opportunities, and 3) validating association data to improve the predictive power of clinical disease screening.
The grant is a Cooperative Agreement and falls under the category of Health. The funding opportunity does not require cost sharing or matching. The maximum award ceiling is $400,000. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. However, non-domestic (non-U.S.) Entities (Foreign Organizations) and non-domestic components of U.S. Organizations are not eligible to apply.
The grant opportunity will close on August 20, 2024, and the archive date is set for September 25, 2024. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-017.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-017.html). If there are any inquiries, they can be directed to NIH Grants Information at grantsinfo@nih.gov.
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed) National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)". This grant aims to support research focused on identifying and characterizing neuroimmune networks, communication pathways, and targets related to HIV and substance use. The grant also seeks to fund research on the discovery of novel modulatory probes/tools that can enhance our understanding of the regulatory mechanisms underlying neuroimmune interactions in the context of HIV and substance use disorder comorbidity. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is November 13, 2024. For more information and to apply, visit the following link: [Research on the Neuro-Immune Axis Grant](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-004.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed) National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)". This grant aims to support research that improves understanding of basic mechanisms and biomarkers of trained immunity, as well as the functional implications of trained immunity in various areas such as immune system development and function, immunity to vaccines or natural infections, and allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation. The grant does not require cost sharing or matching requirements and falls under the category of Health. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The grant has a closing date of January 7, 2027, and more information can be found at the following link: [Understanding Mechanisms and Outcomes of Trained Immunity Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-24-112.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.